A gene-centric study of common carotid artery remodelling by Harrison, Seamus C. et al.
at SciVerse ScienceDirect
Atherosclerosis 226 (2013) 440e446Contents lists availableAtherosclerosis
journal homepage: www.elsevier .com/locate/atherosclerosisA gene-centric study of common carotid artery remodellingSeamus C. Harrison a,*, Delilah Zabaneh b, Folkert W. Asselbergs r,s,t, Fotios Drenos a,
Gregory T. Jones e, Sonia Shah b, Karl Gertowh, Bengt Sennblad h, Rona J. Strawbridge h,
Bruna Gigante i, Suzanne Holewijn q, Jacqueline De Graaf q, Sita Vermeulen q,
Lasse Folkersen h, Andre M. van Rij e, Damiano Baldassarre j, Fabrizio Veglia j,
Philippa J. Talmud a, John E. Deanfield v, Obi Agu x, Mika Kivimaki c, Meena Kumari c,
Matthew J. Bown d,1, Kristiina Nyyssönen k, Rainer Rauramaa l, Andries J. Smit m,
Anders Franco-Cereceda v, Philippe Giral n, Elmo Mannarino o, Angela Silveira h,
Ann-Christine Syvänenp, Gert J. de Borst u, Yolanda van der Graaf s, Ulf de Faire i,
Annette F. Baas f, Jan D. Blankensteijn g, Nicholas J. Warehamw, Gerry Fowkes y,
Ionna Tzoulaki y, Jacqueline F. Price y, Elena Tremoli j, Aroon D. Hingorani c,
Per Eriksson h, Anders Hamsten h, Steve E. Humphries a
aCentre for Cardiovascular Genetics, UCL, UK
bUCL Genetics Institute, UK
cGenetic Epidemiology Group, UCL, UK
dDepartment of Cardiovascular Sciences, Leicester University, UK
eUniversity of Otago, Dunedin, New Zealand
fUniversity Medical Center Utrecht, Utrecht, The Netherlands
gDivision of Vascular Surgery, University Medical Center, Nijmegen, The Netherlands
hAtherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
iDivision of Cardiovascular Epidemiology, Institute of Environmental Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
jDepartment of Pharmacological Sciences, University of Milan, Monzino Cardiology Center, IRCCS, Milan, Italy
kResearch Institute of Public Health, School of Public Health and Clinical Nutrition, University of Kuopio, Finland
l Foundation for Research in Health Exercise and Nutrition, Kuopio Research Institute of Exercise Medicine, Kuopio, Finland
mDepartment of Medicine, University Medical Center Groningen, Groningen, The Netherlands
nAssistance Publique e Hopitaux de Paris, Service Endocrinologie-Metabolisme, Groupe Hôpitalier Pitie-Salpetriere,
Unités de Prévention Cardiovasculaire, Paris, France
o Internal Medicine, Angiology and Arteriosclerosis Diseases, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy
pMolecular Medicine Unit, Department of Medical Sciences, Uppsala University, Sweden
qDepartment of Endocrinology & General Internal Medicine, Division of Vascular Medicine (463), Radboud University, Nijmegen Medical Centre,
P.O. Box 9101, The Netherlands
rDepartment of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands
s Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands
tDepartment of Medical Genetics, Biomedical Genetics, University Medical Center, Utrecht, The Netherlands
uDepartment of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
vVascular Physiology Unit, Institute of Cardiovascular Sciences, University College London, London, UK
wMRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke’s Hospital Cambridge, UK
xDepartment of Vascular Surgery, University College London Hospital, UK
yCentre for Population Health Sciences, Edinburgh University, UKa r t i c l e i n f o
Article history:
Received 9 August 2012
Received in revised form
12 October 2012* Corresponding author. BHF Laboratories, Departm
Street, London WC1E 6JF, UK. Tel.: þ44 (0)20 7679 69
E-mail address: seamus.harrison@ucl.ac.uk (S.C. H
1 On behalf of the Aneurysm Consortium.
0021-9150  2012 Elsevier Ireland Ltd.
http://dx.doi.org/10.1016/j.atherosclerosis.2012.11.002
Open access unda b s t r a c t
Background: Expansive remodelling is the process of compensatory arterial enlargement in response to
atherosclerotic stimuli. The genetic determinants of this process are poorly characterized.
Methods: Genetic association analyses of inter-adventitial common carotid artery diameter (ICCAD) in the
IMPROVE study (n ¼ 3427) using the Illumina 200k Metabochip was performed. Single nucleotideent of Medicine, Centre for Cardiovascular Genetics, University College London (UCL), The Rayne Building, 5 University
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Carotid arterypolymorphisms (SNPs) that met array-wide significance were taken forward for analysis in three further
studies (n ¼ 5704), and tested for association with Abdominal Aortic Aneurysm (AAA).
Results: rs3768445 on Chromosome 1q24.3, in a cluster of protein coding genes (DNM3, PIGC, C1orf105)
was associated with larger ICCAD in the IMPROVE study. For each copy of the rare allele carried, ICCAD
was on average 0.13 mm greater (95% CI 0.08e0.18 mm, P ¼ 8.2  108). A proxy SNP (rs4916251,
R2 ¼ 0.99) did not, however, show association with ICCAD in three follow-up studies (P for
replication ¼ 0.29). There was evidence of interaction between carotid intima-media thickness (CIMT)
and rs4916251 on ICCAD in two of the cohorts studies suggesting that it plays a role in the remodelling
response to atherosclerosis. In meta-analysis of 5 caseecontrol studies pooling data from 5007 cases and
43,630 controls, rs4916251 was associated with presence of AAA 1.10, 95% CI 1.03e1.17, p ¼ 2.8  103,
I2 ¼ 18.8, Q ¼ 0.30). A proxy SNP, rs4916251 was also associated with increased expression of PIGC in
aortic tissue, suggesting that this may the mechanism by which this locus affects vascular remodelling.
Conclusions: Common variation at 1q24.3 is associated with expansive vascular remodelling and risk of
AAA. These findings support a hypothesis that pathways involved in systemic vascular remodelling play
a role in AAA development.
 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.Fig. 1. Analysis flow for this study.1. Introduction
Arteries are dynamic vascular conduits that can remodel in
response to atherosclerosis [1]. Cardiovascular disease is character-
ized by thickening of the intima-media portion of the vessel and
plaque formation, reduced vessel elasticity and increased vessel size.
The process bywhich the vessel enlarges tomaintain flow through is
diseased lumen is known as expansive vascular remodelling [1]. This
is generally considered to be a beneficial physiological response but
may actually have deleterious effects such as plaque instability and
aneurysm formation [2]. For example, excessive expansive arterial
remodelling in the coronary circulation has been associated with an
increased risk of coronary heart disease events [3] and may be
associated with development of aneurysms [4].
It is known that the common carotid artery enlarges & remodels
in response to damaging cardiovascular risk factors [5] and that
there is a strong correlation between carotid intima-media thick-
ness (CIMT) and inter-adventitial common carotid artery diameter
(ICCAD) [6]. Furthermore, there is evidence of an association
between larger common carotid arteries and increased risk of
cardiovascular endpoints such as coronary heart disease, stroke and
abdominal aortic aneurysm (AAA) [7,8]. These observations,
therefore, suggest that carotid artery size may be a marker of
arterial remodelling in response to atherosclerosis.
It has been hypothesised that expansive arterial remodelling has
a genetic component [9] but genetic studies of carotid phenotypes
to date have focused upon carotid intima-media thickness (CIMT)
[10] and carotid artery stiffness [11], with none specifically focused
on expansive remodelling/ICCAD as a trait. In this study we inves-
tigated the genetic determinants ICCAD, as a marker of vascular
remodelling, in large population-based studies. Variants found to
be associated with ICCAD were then tested for an association with
AAA, a disease thought to result from excessive expansive arterial
remodelling.
2. Methods
2.1. Study populations e carotid artery phenotypes
A flow diagram of the overall study design is demonstrated in
Fig. 1. The study populations used in this study are described in
detail in the supplementary methods. Briefly, the IMPROVE study
recruited individuals with at least three cardiovascular risk factors
but free from prevalent cardiovascular disease at baseline. The
Whitehall and Nijmegen Biomedical Study recruited healthy pop-
ulation cohorts and the SMART study recruited individuals who had
already suffered a first arterial disease event. The first stage of the
study involved genetic association analysis of ICCAD in the IMPROVEstudy (n ¼ 3430) [12]. SNPs that met array-wide significance were
taken forward for follow-up studies in theWhitehall II study (WHII)
(n ¼ 2110) [13], the Secondary Manifestations of Arterial Disease
Study (SMART, n ¼ 3062) [14] and the Nijmegen Biomedical Study
(NBS, n ¼ 532, www.nijmegenbiomedischestudie.nl). All studies
had full ethical approval.
2.2. Study populations e AAA
Briefly, for the genetic association analyseswe used data fromfive
caseecontrol studies of AAA. All studies definedAAAas an infra-renal
aortic diameter  3 cm by ultrasound or computed tomography
imaging, or previous AAA rupture/repair. The Aneurysm Consortium
(AC)Genome-Wide association Study of Abdominal Aortic Aneurysm
recruited 1758 cases of AAA from centres across the UK andWestern
Australia. Control data were taken from the Wellcome Trust Case
Control Consortium (n¼ 5400) [15]. TheNewZealand Study included
1326 individuals with AAA and disease free controls 1265 controls
[16]. The Secondary Manifestations of ARTerial disease (SMART)
study included data from 631 cases of AAA and 6342 AAA free
controls recruited from University Medical Center Utrecht, the
Netherlands. In the Utrectht Study 840 individuals with AAA were
recruited to the “Genetics AAA” study and 2791 controls [16]. The
Iceland study included 452 AAA cases and 27,712 controls [16]. All
studies had full ethical approval.
2.3. Measurement of carotid phenotypes (ICCAD & CIMT)
ICCAD for all studies is the mean of the inter-adventitial
distances of the left and right carotid arteries, measured in the
2nd cm from the carotid bifurcation. For CIMT, the IMPROVE study
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centres. The far walls of the left and right common carotids were
visualised at three angles (lateral, anterior and posterior) and
recorded. For the common carotid artery, a number of measures
were recorded (see Supplementary data). For the analyses pre-
sented here, the maximum IMT value in the 1st cm of common
carotid proximal to the bifurcation was used. For the WHII study,
the carotid bulb was identified, and longitudinal 2-dimensional
ultrasonographic images of the common carotid artery 1e2 cm
proximal to the carotid bulb were obtained. The optimal
longitudinal image was acquired on the R-wave of the ECG, and
continuously recorded for 5 s. Measurements of the posterior
wall of the artery were made from stored images with electronic
calipers. CIMT was calculated as the distance between the first
bright light (lumen-intima interface) and the leading edge of the
second bright light (media-adventitia interface). The 3 maximum
measures from the right carotid artery in 3 different frames, and
the 3 maximum measures from the left common carotid artery in
3 different frames were averaged and this is the value used in the
analyses. For the SMART study, the left and right common carotid
arteries were examined in the anterolateral, posterolateral, and
mediolateral directions. Patients were examined in the supine
position, with the head turned 45 from the side being scanned.
The reference point for measurement of the IMT was the
beginning of the dilatation of the carotid bulb, with loss of the
parallel configuration of the near and far walls of the common
carotid artery. An R-waveetriggered optimal longitudinal image
of the far wall was frozen. On this image, the sonographer traced
the leading edges corresponding to the transition zones between
lumen-intima and media-adventitia over a length of 1 cm proximal
to the reference point. The total intima-media surface of this
selected area was calculated online by built-in software of the
ultrasound system. The mean IMT of the 6 measurements in each
patient was calculated. For the NBS, longitudinal images of themost
distal cm of both the far wall and the near wall of both common
carotid arteries were obtained in the optimal projection (antero-
lateral, lateral or posterolateral). All measurements were carried
out in end-diastole using the R-wave of a simultaneously recorded
ECG as a reference frame. The outcome variable was defined as the
mean IMT at the optically thickest part of the common carotid.
Quality control measures and reproducibility statistics for CIMT in
each of the studies is reported elsewhere [12,17e19].
2.4. Genotyping and quality control
The IMPROVE and WHII were genotyped using the Metabochip,
a custom Illumina iSelect genotyping array that captures DNA
variation at regions identified by meta-analyses of GWA studies for
diseases and traits relevant to metabolic and atherosclerotic/
cardiovascular endpoints, comprising approximately 200,000 SNPs.
The IMPROVE study (the discovery cohort), enrolled 3711 subjects
in five different European countries, 3612 of which had both
phenotype and genotype data available. Individual level QC exclu-
sion criteria included call rates <0.95, results of identity by state
(IBS) estimations (e.g. unverified cryptic relatedness), verified
relatedness, estimated inbreeding (excessive homozygosity), and
discrepancy between recorded and genotype-determined sex,
resulting in 140 exclusions. Multidimensional scaling (MDS) anal-
ysis and calculation of the genomic inflation factor lambda was
performed to evaluate population substructure, using PLINK 1.07
(http://pngu.mgh.harvard.edu/wpurcell/plink/). MDS analysis was
performed using largely uncorrelated SNPs obtained by applying
a filter of pair-wise correlation of r2 < 0.5 within a 50 SNP window,
iteratively shifted 5 SNPs along the sequence, which revealed
significant population substructure. An additional 45 individualswere excluded based on results of theMDS analysis or self-reported
non-Caucasian ethnicity. In order to adjust for the identified pop-
ulation substructure, the first threeMDS dimensions were included
as covariates in subsequent association analyses. QC exclusion
criteria for SNPs were genotype call rates <0.90, highly significant
deviation from HardyeWeinberg equilibrium (P < 5  107) and
minor allele frequency (MAF) < 0.005. Following QC procedures,
3427 individuals and 127,830 autosomal SNPs were included in the
association analysis. For WHII, following QC there was data for
130,216 SNPs in 2110 individuals. The genomic inflation factor was
1.02 indicating no evidence of inflation of the test statistic in each of
the analyses due to population structure or other sources. A full
summary table of QC results is provided in Supplementary Table 1.
For the SMART study wet-lab genotyping for single nucleotide
polymorphism (SNP) analysis was carried out by KBiosciences,
Hertfordshire, UK (www.kbioscience.co.uk) using their proprietary
KASPar PCR technique and Taqman Genotype calling was carried
out using an automated system, the results of which were checked
manually by study personnel using SNPviewer software. Individ-
uals from both the Aneurysm Consortium GWAS (AC) were geno-
typed with the Illumina 660k chip. Individuals from New Zealand
(NZ) caseecontrol AAAGWASwere genotyped using the Affymetrix
6.0 gene-chip, whilst individuals from Utrecht and Iceland were
genotyped with the Illumina HumanHap370 or HumanHap610 SNP
chips. For the AC, Iceland and Utrecht studies, rs4916251 was
directly genotyped (i.e. not imputed). Analysis of the AC dataset was
adjusted for MDS co-ordinates to account for population structure
as described in the initial publication [15].
2.5. eQTL studies in aortic tissue
Aortic tissue biopsies (thoracic aorta media n ¼ 138, thoracic
aorta adventitia n ¼ 133) were taken from patients undergoing
aortic valve surgery in the Advanced Study of Aortic Pathology
(ASAP) study. Aortic biopsies were divided into intimal-medial and
adventitial halves. Peri-aortic fat was removed from the adventitial
specimens where present. RNA from the tissue biopsies was
hybridized to Affymetrix ST 1.0 Exon arrays and obtained scans
were RNA normalized and log-transformed. Analyses were per-
formed with imputed genotypes from circulating blood DNA (Illu-
mina 610w-Quad BeadArrays). The full methods for this study have
been described previously [21].
2.6. Statistical analyses
CCAD was normally distributed and therefore not transformed.
Association analysis was performed using linear regression,
adjusting for age andgenderwith the assumptionof additive genetic
effects using PLINK v1.07 (http://pngu.mgh.harvard.edu/wpurcell/
plink/). For IMPROVE additional adjustment for the first three
multidimensional scaling (MDS) componentswas applied to control
for population structure. Meta-analysis was performed using
a fixed-effect model with inverse variance weighting and a calcula-
tion of two homogeneity statistics: Cochran’s Q and I2. The a priori
threshold for array-wide statistical significance was established as
P < 8.39  107 through approximation of the total number of
uncorrelated SNPs on the Metabochip with the number of principal
components explaining >99.5% of the total SNP variation, using
a block size of 8192 SNPs [22,23]. This number was then used for
a standard Bonferroni correction to set the threshold for array-wide
significance for a two-sided test at the 5% level. For caseecontrol
analysis of AAA, summary effects from each of the studies were
combined using fixed effects meta-analysis. Aortic diameter was
log-transformed prior to analysis. To determine if the identified loci
were associated with expansive remodelling in response to
Fig. 2. Manhattan plot for association results by chromosome between 127,998
SNPs and CCAD in the IMPROVE study (red-line ¼ array-wide significance,
8.39  107). Each point on the plot represents the log10 p-value for the associ-
ation between individual SNPs and CCAD. Manhattan plot created in R statistical
package (http://www.r-project.org/).
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SNPs showing a suggestive association on the discovery analyses
(P<1105). Themain effects of the SNPandCIMTwere included in
the regression Equation (1). The interaction term (SNP*CIMT) is the
product of the number of alleles at the locus (1,2,3) and standardized
CIMT.
ICCAD ¼ ß0 þ ßage þ ßsex þ ßSNP þ ßCIMT þ ßSNPCIMT (1)
For SNP-AAA association, logistic regression adjusted for age
and gender was performed. In the AC dataset, additional covariates
were multidimensional scaling co-ordinates to adjust for pop-
ulation substructure as previously described [15]. Study specific
odds ratios and corresponding standard errors were pooled using
inverse weighted meta-analysis using the “metan” command in
Stata V10.
3. Results
3.1. Genetic variants associated with ICCAD
Demographic information for each of the cohorts is shown in
Table 1. The results for the 127,730 SNPs tested in the IMPROVE
discovery cohort are shown in Fig. 2, organised by chromosome
and genomic position in a Manhattan plot. There was a strong
association between variants at 1q24.3 and greater ICCAD (Fig. 3).
Details of all SNPs that showed a suggestive association
(p < 1  105) with ICCAD are provided in the supplementary
data. The lead SNP in the discovery analysis was rs3768445 (MAF
18%) and for each copy of the rare allele ICCAD increased by
0.13 mm (95% CI 0.08e0.18 mm, P ¼ 8.2  108). Rs4916251 was
selected for further study because of genotype availability in
follow-cohorts. This SNP is in high LD with rs3768445 (R2 ¼ 0.99)
with a similar effect size in the discovery study (0.12 mm per
allele, 95% CI 0.08e0.17, P ¼ 1.89  107). In follow-up studies
there was no association between rs4916251 and ICCAD in anal-
ysis from 5755 individuals from three cohorts (per allele change
in ICCAD ¼ 0.02 mm, 95% CI -0.02e0.06, P ¼ 0.28).
3.2. Interaction with CIMT & association with expansive arterial
remodelling
To investigate the whether or not the variants associated with
ICCAD in the IMPROVE discovery were associated with expansive
vascular remodelling further analysis, accounting for CIMT as
a marker of atherosclerotic disease burden was performed. In all
studies there was a strong association between CIMT and ICCAD as
expected (Supplementary data). There was evidence of interaction
between the lead SNPs on Chromosome 1q24.3 and CIMT in the
IMPROVE study (Pinteraction ¼ 4  104). There was also evidence of
interaction in the WHII (Pinteraction ¼ 0.004), but not the SMARTTable 1
Demographic details of studies used in the ICCAD analyses. Continuous data are
expressed as mean (sd).
IMPROVE
(n ¼ 3430)
WHII
(n ¼ 2110)
SMART
(n ¼ 3062)
NBS
(n ¼ 532)
Age (yrs) 64 (54e79) 61 (50e73) 56(49e66) 63 (51e72)
Male (%) 48 77 68 51
CIMT (mm) 0.86 (0.16)
Mean 1.17
(0.33) Max
0.79 (0.15)
Max
0.88 (0.27)
Mean
0.86 (0.11)
Max
CCAD (mm) 7.81 (0.86) 6.17 (0.73) 7.79 (1.1) 6.07 (0.83)
SBP (mm Hg) 141 (18) 127 (16) 141 (20) 129 (6)
DBP (mm Hg) 82 (9.7) 74 (10) 80 (11) 78 (5)
Current
smokers (%)
15 10 32 15Study (Pinteraction ¼ 0.34) or the NBS (Pinteraction ¼ 0.79). Graphical
representations of the interactions in IMPROVE and WHII are
included in the Supplementary data. For each copy of the rare allele
the change in ICCAD accompanied by a one standard deviation
increase in CIMT was approximately 0.08 mm greater (95%
CI ¼ 0.04e0.13). In subgroup analysis, by tertile of CIMT, there was
evidence of stronger effect for the SNP in the top tertiles of CIMT
with a stepwise increase in the meta-analysis effect with each
increment in CIMT tertile (Fig. 4 & Supplementary data), again
suggesting that this variant is associated with a remodelling
response to atherosclerosis. When the two highest tertiles of CIMT
are considered together, carriage of the rare allele was associated
with 0.09 mm increase in ICCAD (95% CI 0.06e0.13,
P ¼ 1.87  107), although there was evidence of heterogeneity
(I2 ¼ 66%), which is probably the result of heterogeneity with
regard to CIMT between the cohorts. We also investigated
subgroups based upon a threshold CIMT value of 0.75 mm (previ-
ously shown to be a value above which risk of events increases
[24]). In individuals with a CIMT greater than this (n ¼ 5468) there
was evidence for an associationwith larger ICCAD (Beta ¼ 0.10, 95%
CI 0.06e0.14, P ¼ 1.15  106) but evidence of considerable
heterogeneity between studies (I2 ¼ 78%, Q ¼ 0.004). There was
no evidence of interaction with systolic blood pressure, height,
smoking status or gender (data not shown) in the IMPROVE and
WHII studies.
3.3. Association of rs4916251 with AAA
In keepingwith previous studies [7], in the SMART study a larger
ICCAD was strongly associated with presence of AAA (OR for AAA
per SD increase in ICCAD¼ 1.67, 95% CI 1.46e1.93, P¼ 6 1013). As
AAA may represent a consequence of excessive expansive arterial
remodelling in response to atherosclerotic stimuli, we examined
the possibility that this SNP may also be associated with risk of
developing AAA. In meta-analysis of 5 caseecontrol studies
Fig. 3. Regional forest of the association between variants at 1q24.3 and ICCAD. The lead SNP value (rs3768445, b ¼ 0.13, P ¼ 8.2  108) is represented by the purple diamond,
while the other points are colour coded by their LD with the lead SNP (as measured by R2). Plot was created using Locuszoom (http://csg.sph.umich.edu/locuszoom/).
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associated with presence of AAA 1.10, 95% CI 1.03e1.17,
p ¼ 2.8  103, I2 ¼ 18.8, Q ¼ 0.30) (Fig. 5). There was no associa-
tion between this SNP and aneurysm diameter (b ¼ 0.016,
P ¼ 0.075) in analysis of aneurysm size from 2906 individuals with
AAA.
3.4. eQTL analysis in aortic tissue
To determine whether or not SNPs at this locus were having an
effect on gene expression we performed allele-specific expression
studies of the nearby genes (DNM3, PIGC, C1ORF105 and C1ORF9)
aortic tissues. The results shown are for rs1023479, which is in high
LD with rs4916251 (R2 ¼ 0.99), as this SNP was not available for
analysis. There was an association between the risk allele andFig. 4. Meta-analysis of the association between rs4916251 and ICCAD by tertile of
CIMT (1st tertile is the lowest, 3rd tertile the highest). Details of the individual study
results are presentated in the Supplementary data.increased expression of PIGC in aortic media (P ¼ 4.4  103, Fig. 6)
and aortic adventitia (P ¼ 0.04). Further in vitro analysis will be
required to delineate the functional variant(s) at this locus and the
mechanism by which it could effect expression of PIGC in the
vasculature.
4. Discussion
Following the initial description of compensatory enlargement
of the coronary arteries by Glagov et al. [1] it has been shown that
expansive arterial remodelling occurs throughout the vasculature
and is an early response to thickening of the intima-media portion
of the vessel [25]. It has also been suggested that excessive
expansive remodelling may actually provoke plaque rupture in the
coronary and carotid circulation, and promote aneurysm degener-
ation in the infra-renal aorta [2]. Although such a remodelling
response may have a genetic component, to our knowledge this is
the first large-scale genetic association study to address thisFig. 5. Forest-plot of association between rs4916251 and AAA. Combined OR (1.10, 95%
CI 1.03e1.17, p ¼ 2.8  103, I2 ¼ 18.8, Q ¼ 0.295).
Fig. 6. Association between rs1023479 (proxy for rs4916251) and expression of PIGC in
aortic media (P ¼ 4.4  103). CC e n ¼ 3, TC e n ¼ 47, TT e n ¼ 83.
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1q24.3 and larger ICCAD in the IMPROVE study was observed, but
this finding was not observed in subsequent studies. The rationale
for investigating an interaction with CIMT was twofold. First, we
were interested to understand if in the IMPROVE study the asso-
ciation was with expansive arterial remodelling (stimulated by
increasing vessel thickness) or simply carotid artery size (an
anthropometric trait). Second, it is possible that association
observed in the IMPROVE study did not replicate because of
between study-heterogeneity. Specifically, participants in the
IMPROVE study were selected to be at high cardiovascular risk (all
the participants have at least 3 cardiovascular risk factors [12]) but
free from prevalent disease. This is in contrast to both the WHII &
NBS studies that used healthy population cohorts and the SMART
study that contained a younger population who had already
experienced a cardiovascular event. There was evidence of an
interaction between rs4916251 and CIMT, suggesting that the
variant is associated with expansive arterial remodelling, rather
than carotid size per se, and this may explain why we did not see
a main effect of the SNP in the follow-up studies. Although on
a continuous scale CIMTmay be a useful predictor of cardiovascular
disease, it is unlikely that values at the lower end of the distribution
represent atherosclerosis [26]. This observation prompted the
subgroup analysis performed in this study. The observation that in
individuals in the highest two tertiles of CIMT there was a strong
association between rs4916251 suggests adds weight to the
hypothesis that the variants identified in this study play a role in
expansive remodelling.
Aneurysm formation may in part, be the result of excessive
outward arterial remodelling. Overall, there was a significant but
modest association between rs4916251 and risk of AAA, which
supports a hypothesis that pathways involved in systemic vascular
remodelling do play a role in AAA development. These data also
demonstrate that in genetic studies of AAA, approaches focussing
on continuous traits associated with AAA may compliment more
traditional caseecontrol study designs.
Variants at 1q24.3 have previously been found to be associated
with adiposity, height and platelet size [27e29], but we found no
association between the lead SNPs for ICCAD and either height or
waist-hip ratio, and the LD between these variants and rs4916251
was low (Supplementary Table 4). Chromosomal deletions at 1q24-
25 result in a phenotype characterised by short stature and skeletal
abnormalities [30] which suggests that this locus plays a role in
extra-cellular matrix remodelling, but the precise underlying
mechanism remains unclear. We have shown that the variantsidentified in this study are associated with altered expression levels
of PIGC in aortic tissue. PIGC encodes phosphatidylinositol N-ace-
tylglucosaminyltransferase subunit C, which forms part of the gly-
cosylphosphatidylinositol (GPI) lipid anchor, a post-translational
modification that allows anchorage of proteins to the plasma
membrane. Understanding how PIGC is involved in vascular diam-
eter and/or remodelling will require further experimental analysis,
and presently there are few data to provide biological insights into
the observed association. This is, however, of potential importance
as therapeutic interventions to target vascular remodelling could
have an important role to play in both treatment of small AAA and
prevention of plaque rupture and subsequent thrombotic events.
4.1. Limitations
The limitations of our study should be considered. The 200,000
SNP chip has in-depth coverage of a large number of genes but it
does not provide genome-wide coverage and it is likely that there
are other variants associatedwith this trait that are not examined. It
would also be relevant to have expression data for genes at the
1q24.3 locus in tissue from early and late stage aneurysms, but this
is not currently available. Perhaps the largest limitation is between
study-heterogeneity with regard to phenotype measurement.
Although the measurement of carotid variables was well stand-
ardised within studies, this may not be the case between studies. In
particular the inter-tertile analysis of CIMT may be hampered by
heterogeneity in the values of CIMT in each group. This highlights
the difficulties in population-based genetic studies of vascular
remodelling traits in which the phenotypic differences are often
subtle. Ideally, there would have been full phenotypic information
from all cohorts, including measures of both CCAD and aorta in the
same individuals, but again this was not available in all studies.
There was evidence the association with was primarily driven by
the AC cohort (sensitivity analysis in Supplementary data) but this
was the largest study with the greatest power to detect a modest
effect. Although the association between rs4916251 and AAA was
only nominally significant (P < 0.05) in one of the cohorts tested
(the AC), it is important to note that the AC was the largest study
with the greatest statistical power, and that the meta-analysis
estimate showed little evidence of heterogeneity (I2 ¼ 13%). For
the AAA association, there was limited phenotype data available, so
multivariate regression models including other covariates such as
blood pressure and lipid parameters was not possible. Finally, for
the expression studies were from thoracic aortic tissue and not the
abdominal aorta, which may have a different pattern of expression.
5. Conclusion
This study has identified variants at 1q24.3 that show associa-
tion with carotid artery remodelling and the risk of developing an
AAA. This may be due to an allele-specific effect of expression of
PIGC in the vasculature. These results provide suggestive genetic
evidence that pathways involved in the systemic vascular remod-
elling in response to atherosclerosis may play a role in AAA risk.
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